Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

BACKGROUND: Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely poor prognosis. We evaluated the expression levels of EpCAM and the in vitro activity of solitomab, a bispecific single-chain antibody construct which targets epithelial-ce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Ferrari, Francesca, Bellone, Stefania, Black, Jonathan, Schwab, Carlton L., Lopez, Salvatore, Cocco, Emiliano, Bonazzoli, Elena, Predolini, Federica, Menderes, Gulden, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609066/
https://ncbi.nlm.nih.gov/pubmed/26474755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-015-0241-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars